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Introduction: High collision-risk physical activity can increase bleeding risk in people with
hemophilia A, as can increasing the time between factor VIII (FVIII) administration and physical
activity. FVIII prophylaxis may be tailored to planned activities to prevent activity-related bleeding.
Aim: To explore the relationship between physical activity levels, FVIII infusion timing, and
occurrence of bleeding in patients with severe/moderately severe hemophilia A without FVIII
inhibitors receiving antihemophilic factor (recombinant) (rAHF; ADVATE®; Baxalta US
Inc., a Takeda company, Lexington, MA, USA).
Methods: SPACE was a 6-month, prospective, multicenter, observational outcomes study
(NCT02190149). Enrolled patients received an eDiary application and a wearable activity
tracker, which recorded physical activity, rAHF infusion, and occurrence of bleeding.
Physical activity risks were ranked using National Hemophilia Foundation criteria.
Results: Fifty-four patients aged 11–58 years (n = 47 prophylaxis, n = 7 on-demand) were
included in the analysis. Patients had a mean (SD) 8.14 (10.94) annualized bleeding rate, and
recorded 4980 intervals between an rAHF infusion and physical activity; 1759 (35.3%) of
these intervals were ≤24 hours. Analysis of recorded eDiary data showed that the risk of
activity-related bleeding did not significantly increase with time between last infusion and
activity, but did increase with higher-risk physical activities. Analysis of activity tracker
recorded data showed that the risk of bleeding reported by patients as spontaneous increased
with prolonging time (≤24 to >24 hours) from last infusion to physical activity start (odds
ratio 2.65, p < 0.05). Joint health data collected at baseline were not included in the
regression analysis because of small sample size; therefore the study could not assess
whether patients with more joint disease at baseline were at higher risk of injury-related
and reported spontaneous occurrence of bleeding.
Conclusion: These results show that activities with a high risk of collision lead to an
increased risk of bleeding. Further investigation is warranted to explore potential benefits of
FVIII infusion timing to reduce the risks of activity-related occurrence of bleeding.
Keywords: hemophilia A, recombinant factor VIII, physical activity, post-authorization
study, prophylaxis, bleeding

Introduction
In people with hemophilia A (PwHA), prophylactic factor VIII (FVIII) replacement
therapy has been the standard of care for bleeding prevention by maintaining
plasma FVIII activity levels of ≥1%.1,2 The World Federation of Hemophilia
Journal of Blood Medicine 2021:12 883–896
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(WFH) 2020 guidelines recommend FVIII activity levels
of ≥3%.3 FVIII prophylaxis reduces frequency of bleeding
with the goal of improving quality of life in PwHA.4–6
Individualized prophylactic regimens that aim to tailor
FVIII levels to lifestyle and physical activity requirements
are likely to offer further beneficial effects in minimizing
bleeding risk while facilitating the physical and psychoso
cial benefits of exercise.7,8
Limited data exist on the relationship between FVIII
levels and bleeding risk in PwHA and physically active
lifestyles. Participation in vigorous, high-risk collision
sports has been associated with a transient increase in
bleeding risk, with most activity-related episodes mani
festing within 1 hour of physical activity.9 While tailoring
FVIII replacement therapy to a patient’s physical activity
pattern is likely to be beneficial, it has only recently
become part of routine practice.10 The evolution of hemo
philia treatment in recent years, including the development
of extended half-life FVIII products and non-factor repla
cement therapies,11 has meant that personalization of treat
ment is now becoming more widespread. Indeed,
personalization of therapy based on each individual’s
activities and lifestyle is recommended in the WFH 2020
guidelines.3
Patient questionnaires have typically been used to
monitor physical activity in relation to occurrence of
bleeding in PwHA. The use of commercial activity track
ers in hemophilia research is limited, but continuous and
long-term monitoring of activity with activity trackers was
suitable in PwHA in an observational prospective study.12
Mobile applications for recording and monitoring occur
rence of bleeding and dosing regimens offer an innovative
method of data collection in clinical studies, with applica
tions in telehealth for promoting appropriate use of clot
ting factors in patients with hemophilia.13
The prospective non-interventional Study of
Prophylaxis, ACtivity and Effectiveness (SPACE)
explored the effect of physical activity levels and timing
of antihemophilic factor (recombinant) (rAHF;
ADVATE®; Baxalta US Inc., a Takeda company,
Lexington, MA, USA) infusion on occurrence of bleeding
in patients with hemophilia A.

Materials and Methods
Study Design and Conduct
This prospective, multicenter, post-authorization, 6-month,
observational outcomes study (NCT02190149) was
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conducted at 21 centers in the United States from
June 2014 to June 2016. The study was approved by
independent ethics committees for all participating sites
and conducted in accordance with standards of good clin
ical practice in effect at the time of the study and the
Declaration of Helsinki. All patients (or their legally
authorized representatives) were provided with informa
tion about the purpose of the study and gave written
consent before enrolment.

Patients
Inclusion criteria were: patients aged 13–65 years with
severe or moderately severe hemophilia A (FVIII ≤2%),
receiving rAHF and with a history of plasma-derived or
recombinant FVIII replacement therapy for ≥150 exposure
days. Patients with hemophilia B (factor IX [FIX] ≤2%)
receiving recombinant factor IX, nonacog gamma (BAX
326, Rixubis®; Baxalta US Inc., a Takeda company,
Lexington, MA, USA) were also eligible, but those results
are not reported here. Patients with an inhibitor titer of
≥0.6 Bethesda units, or being treated for an inhibitor, or
who had elective surgery planned within 6 months after
enrolment that might interfere with daily activities, or
those continuously requiring walking assistance devices
were not eligible for enrolment.

Procedures
At baseline, investigators recorded treatment regimens
(prophylaxis vs on-demand) and infusion timing schedules
for patients receiving prophylactic rAHF (routine prophy
laxis: 20–40 IU/kg every other/every third day; dosage
targeted to maintain FVIII trough levels ≥1%).13 Patients
remained on rAHF treatment as directed by their physician
throughout this non-interventional study (12-month
recruitment period, 6-month observation period). Patients
received a customized eDiary smartphone application
(Exco InTouch, an ERT company, Nottingham, United
Kingdom) and a wearable activity tracker (Fitbit®; Fitbit,
Inc., San Francisco, CA, USA), which recorded data dur
ing the observation period (ie, period between eDiary/
activity tracker start and end dates) and at study comple
tion (Figure 1A). The eDiary application was downloaded
onto the patient’s smartphone and served as the primary
data collection tool for patient physical activity, infusion
timing, and occurrence of bleeds; if the patient did not
have access to a suitable phone, one was provided for the
study duration. During the observation period, upon occur
rence of a bleeding episode, patients recorded in the
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Patient screening
• Moderately severe or severe
hemophilia A (FVIII level ≤2%)
• Aged 13-65 years
• Receiving rFVIII
• Prior treatment with FVIII ≥150 EDs

6-month observation period

Patients receive:
• SPACE eDiary
• Activity tracker

Patients use:
• SPACE eDiary
• Activity tracker

Baseline CRF (investigator reported)
• Demographics
• Medical history
• Prescribed treatment regimen
• Bleeding history
• Available joint outcome measurements
• Number of target joints
• Other¶

eDiary (patient reported)
• Treatment (eg, infusion timing)
• Physical activity
• Occurrence of bleeding episodes

Study completion

Patients use:
• SPACE eDiary

eDiary survey
• Changes in treatment regimen
• Activity level
• HAL or PedHAL questionnaire††

Safety calls to patient by site every
month
Data entry reminder phone calls to
patients as needed

eDiary baseline survey (patient reported)
• Activity levels
• Satisfaction with activity level
• Bleeding history
HAL or PedHAL questionnaire

B
Enrolled
(N = 64)
Failed screening
(n = 3)
Passed screening
(n = 61)
Excluded from rAHF treatment analysis
Treated with rFIX (n = 1)
Discontinued study
(n = 19)
Patient with 2 SAEs
(n = 1)
Investigator withdrew†
(n = 4)
Individual withdrew‡
(n = 11)
Other reasons
(n = 3)§

Treated with rAHF
Safety population (n = 60)

Excluded from rAHF treatment analysis
No infusions recorded (n = 2)
No activity tracker data recorded (n = 2)

Activity data in eDiary
(n = 56)
Excluded from rAHF treatment analysis
No infusions recorded (n = 2)
Activity data and rAHF infusion data
in eDiary
Full analysis set (n = 54)
Completed study
(n = 42)

Figure 1 (A) SPACE study design and timing of assessments. (B) Patient disposition. †For inactivity (n = 1), loss to follow-up (n = 1), non-compliance with required
reporting (n = 1), or non-compliance with data entry (n = 1). ‡Technical problems, difficulty committing time (n = 6); non-compliance, withdrew consent (n = 5). §Noncompliance (n = 1) and technical difficulties (withdrawn per protocol; n = 2). ¶Other data includes number of concomitant medications, non-drug therapies and available
pharmacokinetic data history. ††Completed 1 week before study end.
Abbreviations: CRF, case report form; ED, exposure day; FVIII, factor VIII; HAL, Hemophilia Activities List; PedHAL, Paediatric Hemophilia Activities List; rFIX,
recombinant factor IX; rAHF, antihemophilic factor (recombinant); SAE, serious adverse event.
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eDiary the doses and reasons for infusions (routine pro
phylaxis or on-demand [ie, treatment for new occurrence
of bleeding]). Lastly, the patients captured changes in
treatment regimen at the time of study completion. Data
collected via the activity tracker included steps taken and
active minutes. Additionally, upon activity-related occur
rence of bleeding, patients indicated what type of activity
was associated with the occurrence of bleeding.

Objectives
The primary study objective was to explore the relation
ship between physical activity level, rAHF infusion tim
ing, and occurrence of bleeding episodes in PwHA during
a 6-month observation period. Secondary objectives
included collecting physical activity data (type, frequency)
using a patient self-reported eDiary and a consumer-based
activity tracker.

Data Collection and Analyses
Estimation of Time Since Last Infusion to Start of
Activity
To estimate the time (ie, number of hours) since the last
rAHF infusion to the start of physical activity, each day
was divided into the following four 6-hour cycles:
Morning, 06:00 to 12:00; afternoon, >12:00 to 18:00;
evening, >18:00 to sleep; and night, 24:00 to <06:00.

Physical Activity
At baseline, patients documented in the eDiary the physi
cal activity type, average number of days per week spent
participating at each risk level, barriers to participation,
and information on FVIII infusions before planned activ
ities. Patients rated their activities in the eDiary according
to the National Hemophilia Foundation “Playing it safe”
activity listing, which identifies a risk collision score asso
ciated with various activities; if an activity was not listed,
patients were asked to estimate the risk level.14 Activities
were thus classified into one of the following three cate
gories based on the associated risk: (1) significant colli
sions are not expected; (2) significant collisions might
occur, and (3) significant collisions are inevitable. During
the observation period, patients recorded type, duration,
and timing of activities undertaken daily in the eDiary.
Timing of physical activity was recorded as a time range
(ie, not the exact time); for the purposes of the analysis,
the “morning” time range was set to start at 06:00 (morn
ing), the “afternoon” time range at 12:00 (noon) and the
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“night” range at 18:00 (night). The activity tracker
recorded daily totals for steps taken and active minutes.

Occurrence of Bleeding
At baseline, patients recalled from memory the number
and location of occurrences of bleeding (eg, total and joint
bleeds) during the 6 months before the date of informed
consent, as well as the number and location of target
joints, which were recorded on the case report form.
Information on bleed history was also compiled from
patient medical records. During the study’s 6-month obser
vation period, patients recorded location, cause (any, activ
ity-related, spontaneous, or other), type (joint or nonjoint), and duration of occurrence of bleeding in the
eDiary (retrospective entry for previous 2 days of data
was permitted). If no end date was recorded for
a bleeding episode, the study site followed up with the
individual for bleed status. If the patient did not record/
report bleed or infusion timing data during the allowed
window of time, the data were considered missing. Only
observed data were used in the analysis.
The number of bleeding episodes that happened during
the study period was summarized by treatment regimen
(prophylaxis or on-demand) vs type of bleed and by age
group vs bleed type. Bleed frequency, annualized bleeding
rate (ABR), and annualized joint bleeding rate (AJBR)
were calculated for patient-level data.

Safety
From the time of informed consent to study completion,
patients reported serious adverse events (SAEs) directly to
study sites (ie, not in the eDiary); additional safety infor
mation was collected during follow-up calls every other
month. SAEs included medical occurrences where the out
come was fatal, life-threatening, required inpatient hospi
talization, or was a medically important event. AEs were
categorized according to the Medical Dictionary for
Regulatory Activities (version 19.0). The potential causal
relationship between rAHF treatment and an SAE was also
evaluated.

Treatment Adherence
Measures of adherence to prophylactic treatment during
the 6-month observation period included dose adherence
(proportion of total prescribed dose actually administered)
and infusion timing schedule adherence vs baseline regi
men. Infusion schedule was calculated both as
a proportion of planned infusions administered and
a proportion of planned infusions administered on
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Compliance to Data Entry
Data entry compliance was calculated as proportion of
days during the observation period with complete entries.
Patients received a motivational phone call every other
month to ensure data entry compliance. Individuals with
no recorded data for 2 consecutive weeks or for a total of 3
weeks were withdrawn from the study. Compliance was
categorized by quintiles.

Data Collection Procedures
Patients were trained to use an integrated web portal (Exco
InTouch database), which linked to the eDiary and activity
tracker data. Data from the eDiary were automatically
exported to the clinical database. Patients had to sync
their activity tracker data to the web portal daily if their
smartphone did not have the required capabilities for auto
matic syncing. A reminder message was sent to patients
after a few days if they forgot to connect their activity
tracker.

Statistics
To obtain 50 evaluable patients, the enrolment target was
60 patients. Because study objectives were exploratory, no
formal power calculations were performed to determine
sample size. Results were summarized by treatment regi
men using descriptive statistics (Table S1 includes vari
ables and subgroup definitions used in the analysis). The
safety population comprised all patients who were treated
with ≥1 rAHF dose. The full analysis set (FAS) population
comprised patients in the SAS with valid eDiary activity
data recorded.
Longitudinal logistic regression models were used to
evaluate the dynamic association between physical activity
levels, time since last infusion to start of physical activity
cycle, and activity-related bleeding risk of patients in the
FAS, regardless of treatment discontinuation. eDiary and
activity tracker data were analyzed separately. Covariates
are described in Table S1. Occurrence of bleeding epi
sodes in each cycle was modelled as a binary dependent
variable, and outcomes were expressed as the odds of
bleeding in a given situation (odds ratio [OR] [95% con
fidence interval (CI)]) vs in absence of the situation (activ
ity vs no activity). For safety data, p-values were
calculated using chi-square or Fisher’s exact tests for
categorical variables.

Journal of Blood Medicine 2021:12
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Results
Patients
Of 64 patients enrolled, 60 with hemophilia A receiving
rAHF were eligible and 54 had both activity and rAHF
infusion data recorded in the eDiary (FAS). Forty-two
patients completed the study; 3 failed screening and 19
discontinued prematurely (Figure 1B). Information on data
entry compliance for both eDiary and activity tracker
entries was available for 53/54 patients, of whom 16
(30.2%) had entries for ≥60% of observation days
(Table S2).
Mean (SD) age at screening was 23.7 (12.1) (range
11.0–58.0) years (Table 1). One patient in the FAS was
younger than the lower age limit for study eligibility (13
years) and received a waiver to permit enrolment. Patients
had a mean (SD) 5.0 (9.0) bleeding episodes (all bleeds) in
the 6 months before providing informed consent. The
majority of patients (47/54) received prophylaxis. The
most common prophylactic dosing schedule at baseline
and during the observation period was three infusions per
week (n = 26, 55.3%), then infusions every second day (n
= 8, 17.0%), then twice per week (n = 7, 14.9%). One
patient in each regimen group at baseline switched regi
mens during the study.

Physical Activity
Physical activity intensity data recorded via the eDiary
were available for 54 patients at baseline and 34 at study
completion. In the 6-month pre-observation period, mean
(SD) number of days per week spent on mild, moderate,
and strenuous activity was 2.74 (2.29), 2.30 (1.70), and
1.65 (1.75), respectively. At study completion, mean (SD)
number of days spent on each activity per week was 2.50
(2.29), 2.50 (1.80), and 2.35 (1.95) days, respectively
(Table 2). Of 34 evaluable patients with available physical
activity data at study completion, 29 (85.3%) patients
reported that they infused prior to activity (27/31 patients
on prophylaxis; 2/3 on-demand regimen).
Among all 54 patients (prophylaxis or on-demand
treatment) during the 6-month observation period, there
were 4980 total intervals recorded between an rAHF infu
sion and the next recorded physical activity (morning,
noon, or night). Overall, patients administered most infu
sions >24 hours before initiating activity (64.7%, 3221/
4980 intervals); 479 (9.6%) intervals were ≥5 days.
Overall, 27.8% of patients infused 1–2 days before starting
an activity; the proportion was consistent across the
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Table 1 Patient Baseline Characteristics
Treatment Regimen
Characteristic

Total N = 54

On-Demand n = 7†

Prophylaxis n = 47†

Age, y, mean ± SD

23.7 ± 12.1

26.6 ± 17.9

23.3 ± 11.3

White

44 (81.5)

6 (85.7)

38 (80.9)

Black
Asian

7 (13.0)
3 (5.6)

0 (0)
1 (14.3)

7 (14.9)
2 (4.3)

25.0 ± 7.3

20.2 ± 5.8

25.7 ± 7.3

2 (0.0–60.0)

3 (0.0–60.0)

2 (0.0–16.0)

1 (0.0–30.0)

3 (0.0–30.0)

1 (0.0–14.0)

0 (0.0–30.0)

1 (0.0–30.0)

0 (0.0–15.0)

Spontaneous
Activity-related

0 (0.0–15.0)
0 (0.0–60.0)

0 (0.0–7.0)
1 (0.0–60.0)

0 (0.0–15.0)
0 (0.0–16.0)

Unknown

0 (0.0–3.0)

0 (0.0–1.0)

0 (0.0–3.0)

0.6 ± 1.4

0.6 ± 1.5

0.6 ± 1.4
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Race, n (%)

Body mass index, kg/m2 mean ± SD‡

No. of bleeding events per patient during the 6 months before enrollment, median (min–max)
All bleeding events
‡

Type
Joint
Non-joint
Cause

Total no. of target joints per patient at screening, mean ± SD

Notes: †One patient, who was treated with prophylaxis at baseline, received only one on-demand treatment during the observation period and was included in the on-demand
group. One patient who was treated on-demand at baseline changed to prophylaxis treatment. ‡Based on a total of 53 patients (on-demand, n = 7; prophylaxis, n = 46).

activity risk level categories. Of 4980 total intervals, 3761
(75.5%) were associated with low-risk activities and 196
(3.9%) with high-risk activities (Table 3).

Occurrence of Bleeding
During the 6-month observation period, 17/54 (31.5%)
patients reported no bleeding episodes (Table S3). The

Table 2 Physical Activity Duration and Intensity at Baseline and Study End (eDiary Data)
Treatment Regimen
Total

On-Demand

Prophylaxis

54

7

47

Strenuous

1.65 ± 1.75

2.57 ± 2.44

1.51 ± 1.61

Moderate
Mild

2.30 ± 1.70
2.74 ± 2.29

2.57 ± 1.90
1.71 ± 2.06

2.26 ± 1.69
2.89 ± 2.31

34

3

31

Strenuous

2.35 ± 1.95

1.67 ± 0.58

2.42 ± 2.03

Moderate
Mild

2.50 ± 1.80
2.50 ± 2.29

2.33 ± 0.58
0.33 ± 0.58

2.52 ± 1.88
2.71 ± 2.28

Baseline (during the 6 months before the study)
Patients, n
Days per week by intensity level, mean ± SD

Study end
Patients, n
Days per week by intensity level, mean ± SD
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Table 3 rAHF Infusions by Time from Most Recent Infusion Before Start of Physical Activity Based on NHF Activity Risk Level (eDiary
Data)
NHF Activity Risk Level
Total N = 54

1 (Low)

1.5 (Low to

2 (Moderate)

Moderate)
Infusion intervals

4980

3761

2.5 (Moderate

3 (High)

to High)

488

935

330

196

Time between infusion and start of activity, n (%)
≤8 h
8–12 h

560 (11.2)
310 (6.2)

412 (11.0)
246 (6.5)

79 (16.2)
28 (5.7)

122 (13.0)
61 (6.5)

32 (9.7)
27 (8.2)

26 (13.3)
13 (6.6)

12–24 h

889 (17.9)

710 (18.9)

55 (11.3)

148 (15.8)

76 (23.0)

44 (22.4)

1–2 d
2–3 d

1382 (27.8)
802 (16.1)

1047 (27.8)
632 (16.8)

130 (26.6)
74 (15.2)

283 (30.3)
124 (13.3)

92 (27.9)
37 (11.2)

52 (26.5)
33 (16.8)

3–5 d

558 (11.2)

411 (10.9)

57 (11.7)

98 (10.5)

31 (9.4)

19 (9.7)

≥5 d

479 (9.6)

303 (8.1)

65 (13.3)

99 (10.6)

35 (10.6)

9 (4.6)

†

Notes: eDairy recorded time of infusions but not activity time. It was assumed that the activity occurred in the morning at 6 AM, afternoon at 12 PM, and night at 6 PM.
Abbreviations: NHF, National Hemophilia Foundation; rAHF, antihemophilic factor (recombinant).

remaining 37 patients reported 185 bleeding episodes in
total. Overall (n = 54), mean (SD) number of bleeds per
person was 3.43 (5.06) for all bleeds, of which 1.52 (2.94)
were reported by patients as spontaneous and 1.39 (2.11)
as related to physical activity. For 31 patients receiving
prophylaxis, there were 3.02 (4.72) bleeds per person (1.21
[2.41] reported by patients as spontaneous, and 1.26 [2.03]

A

reported as activity-related); for six patients receiving ondemand treatment, there were 6.14 (6.77) bleeds per per
son (3.57 [5.13] reported as spontaneous and 2.29 [2.63]
reported as activity-related).
At study end, mean (SD) ABR for all bleeds was 8.14
(10.94) among patients with ≥5 months of data during the
observation period. ABR for all bleeds was higher for

B
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35
15.59
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30
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25
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included in analysis, n†

20
15
4.09
2.81

10
5

0

0
Total
(N = 40)†

On demand
(n = 4)

Prophylaxis
(n = 36)

Total
(N = 40)†

Treatment regimen

On demand
(n = 4)

Prophylaxis
(n = 36)

Treatment regimen

ABR
Mean (SD)

8.14 (10.94)

19.14 (13.33)

6.92 (10.14)

4.09 (8.05)

15.59 (14.52)

2.81 (6.11)

Median
(min-max)

3.97
(0-40.36)

20.05
(1.96-34.50)

2.99
(0-40.36)

0
(0-34.50)

13.93
(0-34.50)

0
(0-32.42)

P value (on
demand vs
prophylaxis)

0.0727

0.0251

Figure 2 Annualized bleeding rates (ABR) at study end by treatment regimen. (A) All bleeds. (B) Joint bleeds. †Patients with ≥5 months of follow-up data.
Abbreviation: AJBR, annualized joint bleeding rate.
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Table 4 Treatment Adherence to Prophylaxis
Age Group
Parameter

Total

Age <18 y

Age ≥18 y

Adherence to dose: Proportion of total prescribed dose administered
Patients, n

43†

19

24

0.65 ± 0.31

0.55 ± 0.26

0.73 ± 0.33

0.0547

47
0.48 ± 0.32

21
0.36 ± 0.27

26
0.57 ± 0.33

0.0351

Patients, n

47

21

26

Mean ± SD

0.64 ± 0.28

0.53 ± 0.21

0.73 ± 0.29
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Mean ± SD
Adherence to schedule (gap between infusions): Proportion of planned infusion administered
according to schedule within a 1-day window
Patients, n
Mean ± SD
Adherence to schedule (number of infusions): Proportion of planned infusions administered
according to schedule within a 1-day window

0.013

†

Note: Five patients were not included due to missing data.

patients receiving on-demand therapy vs prophylaxis
(Figure 2A). AJBR was 4.09 (8.05) overall, with
a higher AJBR observed for patients receiving ondemand treatment vs prophylaxis (Figure 2B).

Safety
Overall, 10 AEs, of which 7 were SAEs, were reported in
7 patients (all on prophylaxis); none of these AEs or SAEs
were considered related to rAHF. The proportion of
patients experiencing AEs did not differ significantly
between age groups (Table S4).

Treatment Adherence and rAHF
Consumption
For dose adherence assessment, the mean (SD) propor
tion of total rAHF dose received vs dose prescribed
was 0.65 (0.31). For schedule adherence, the mean
(SD) proportion of infusions received on schedule vs
infusions planned was 0.48 (0.32) based on gap
between infusions and 0.64 (0.28) based on number
of infusions (Table 4); 19.1% (9/47) of patients
received 80–100% of the prescribed prophylactic
rAHF dose and 19.1% (9/47) received 80–100% of
planned infusions (based on gap between infusions).
Individuals aged ≥18 years were more adherent to
prophylactic rAHF than those aged <18 years, with
statistically significant differences for schedule adher
ence but not dose adherence (Table 4).
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Risk of Physical Activity-Related and
Spontaneous Bleeds
According to data recorded in the eDiary, activity-related
bleeding risk tended to increase commensurately with phy
sical activities classified as higher risk (odds of activityrelated bleeding for level 3 risk activity were 5 times that
for no activity in those receiving prophylaxis; OR [95% CI]
5.06 [1.33–19.27], p = 0.0173; Table 5A). There was no
significant correlation between bleeds recorded in the
eDiary as activity-related and the time since last rAHF
infusion.
Regression analysis of activity tracker data showed no
significant relationship between odds of physical activityrelated occurrence of bleeding with either physical activity
type or time between last rAHF infusion and start of
physical activity (Table 5B), although prolonging time
from last rAHF infusion to start of physical activity from
≤24 to >24 hours was significantly associated with higher
risk of bleeding reported by patients as spontaneous (OR
range, 2.61–2.65; all p < 0.05; Table 6).

Discussion
This study was designed to elucidate the temporal relation
ship between physical activity levels, FVIII infusion timing,
and occurrence of bleeding episodes in adolescents and
adults with hemophilia A who were prescribed rAHF in the
United States. As expected, a higher-risk physical activity
correlated with greater probability of bleeding reported as
physical activity-related. However, eDiary and activity
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Table 5 Effect of Physical Activity and Time Since Last rAHF Infusion to Start of Activity on Risk of Bleeding Events Reported as
Activity-Related by Patients with Hemophilia A Receiving Prophylactic rAHF: Logistic Regression Model Based on Data from the (A)
eDiary and (B) Activity Tracker
A. eDiary data (N = 47)†,‡
Parameter

Odds ratio

95% CI

p-value

1.74

0.81–3.77

0.1571
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Model 1: Activity vs no activity
Activity: Yes vs no
Time since last infusion to activity start§:
12–24 vs ≤12 h

1.17

0.53–2.59

0.6966

1.00

0.36–2.77

0.9928

1.00

0.98–1.02

0.9030

Risk levels 1 and 1.5 vs no activity
Risk levels 2 and 2.5 vs no activity

1.65
1.92

0.77–3.56
0.83–4.44

0.2006
0.1255

Risk levels 3 vs no activity

5.06

1.33–19.27

0.0173

12–24 vs ≤12 h

1.13

0.51–2.51

0.7696

>24 vs ≤12 h

1.01

0.37–2.75

0.9892

1.00

0.97–1.02

0.8697

1–30 min of activity vs no activity
31–60 min of activity vs no activity

1.47
1.95

0.56–3.82
0.71–5.36

0.4331
0.1938

>60 min of activity vs no activity

2.92

0.94–9.14

0.0650

1.15
1.02

0.53–2.51
0.37–2.77

0.7265
0.9757

Last infusion dose, IU/kg

1.00

0.97–1.02

0.8794

Age

0.95

0.89–1.01

0.1152

>24 vs ≤12 h
Last infusion dose, IU/kg
Model 2: Physical activity by risk level
Activity level¶

Time since last infusion to activity start§:

Last infusion dose, IU/kg
Model 3: Time spent on physical activities

Time since last infusion to activity start§:
12–24 vs ≤12 h
>24 vs ≤12 h

Model 4: Time spent on the physical activity by risk level
Every 30 min spent on activity risk levels 1 and 1.5
Every 30 min spent on activity risk levels 2 and 2.5

1.03
1.05

1.01–1.04
0.93–1.18

0.0043
0.4673

Every 30 min spent on activity risk level 3

1.23

1.18–1.29

<0.0001

12–24 vs ≤12 h

1.20

0.55–2.62

0.6423

>24 vs ≤12 h

1.02

0.38–2.72

0.9648

Last infusion dose, IU/kg

1.00

0.97–1.02

0.8039

Age

0.96

0.91–1.01

0.1415

Walking (risk level 1)
Body sculpting (risk level 1.5)

1.19
1.61

1.08–1.30
1.00–2.59

0.0002
0.0502

Running and jogging (risk level 2)

2.09

1.31–3.32

0.0019

Time since last infusion to activity start§:

Model 5: Time spent on common physical activities
Every 30 min spent on common activities

(Continued)
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Table 5 (Continued).
Power lifting (risk level 3)

7.58

3.95–14.55

<0.0001

Other activities

1.02

1.00–1.04

0.0658

1.17
1.01

0.52–2.62
0.36–2.86

0.7055
0.9811

1.00

0.97–1.02

0.8205

0.95

0.88–1.02

0.1243

Odds ratio

95% CI

p-value

Activity calories: 1–1000 vs 0

2.75

0.70–10.88

0.1491

Activity calories: >1000 vs 0
Time since last infusion to activity start††:

3.00
0.92

0.77–11.68
0.45–1.88

0.1124
0.8148

0.99
0.96

0.96–1.01
0.91–1.02

0.3102
0.1848

Steps: 1–6000 vs 0

2.49

0.64–9.69

0.1891

Steps: >6000 vs 0
Time since last infusion to activity start††:

3.15
0.92

0.81–12.2
0.45–1.88

0.0975
0.8308

0.99
0.96

0.96–1.01
0.91–1.02

0.2959
0.1617

1–120 min of activity vs no activity

2.57

0.50–13.24

0.2584

121–240 min of activity vs no activity
>240 min of activity vs no activity

2.25
3.48

0.67–7.62
0.89–13.63

0.1920
0.0731

Time since last infusion to activity start††:

0.92

0.45–1.89

0.8206

>24 vs ≤24 h
Last infusion dose, IU/kg

0.99

0.97–1.01

0.3022

Age

0.96

0.91–1.02

0.1608

Every 30 min spent on lightly active activity
Every 30 min spent on fairly active activity

1.03
1.06

0.95–1.12
0.90–1.26

0.4279
0.4786

Every 30 min spent on very active activity

1.04

0.73–1.47

0.8360

Time since last infusion to activity start††:
>24 vs ≤24 h

0.91

0.45–1.87

0.8055

Last infusion dose, IU/kg

0.99

0.97–1.01

0.3322

Age

0.96

0.91–1.01

0.1472

Time since last infusion to activity start§:
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12–24 vs ≤12 h
>24 vs ≤12 h
Last infusion dose, IU/kg
Age
†

B. Activity tracker data (N = 46)
Parameter
Model 1: Activity calories

>24 vs ≤24 h
Last infusion dose, IU/kg
Age
Model 2: Steps performed

>24 vs ≤24 h
Last infusion dose, IU/kg
Age
Model 3: Time spent on activities

Model 4: Time spent on the activity by risk level

†

Notes: P-values of <0.05 indicate statistically significant associations. Logistic regression models were used to evaluate the dynamic association between physical activity
and time since last infusion on bleeding risk with time-varying activity level in the current cycle, time since last rAHF infusion to the beginning of the activity cycle, and age at
baseline (fixed covariate). Generalized estimating equations were used to account for intra-person correlations. ‡Among the 47 patients receiving prophylaxis, 22
experienced a total of 50 activity-related bleeding events that were included in this analysis. §eDiary data did not record the exact timing of activities. Time since last
rAHF infusion was estimated by dividing each day into four cycles (6 AM to 12 PM [morning], 12 PM to 6 PM [afternoon], 6 PM to sleep [evening], 12 AM to 6 AM [night]),
with activities assumed to start at the beginning of a designated cycle. ¶Risk levels rate from 1 (low) to 3 (high); see Table S1 for more details. ††The activity tracker did not
record the exact timing of activity but reported the number of activity minutes by risk level daily. Therefore, the data were structured by date for each patient.
Abbreviation: rAHF, antihemophilic factor (recombinant).
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Table 6 Effect of Physical Activity and Time Since Last rAHF Infusion to Start of Activity on the Risk of Bleeding Events Reported as
Spontaneous by Patients with Hemophilia A Receiving Prophylactic rAHF: Logistic Regression Model (Activity Tracker Data; N = 46)†,‡
Parameter

Odds Ratio

95% CI

p-value

Activity calories: 1–1000 vs 0
Activity calories: >1000 vs 0

2.43
2.25

1.01–5.87
0.90–5.62

0.0484
0.0840

Time since last infusion to activity start§:

2.65

1.05–6.67

0.0386

>24 vs ≤24 h
Last infusion dose, IU/kg

0.98

0.95–1.00

0.0644

Age

0.99

0.96–1.02

0.4659

Steps: 1–6000 vs 0

2.76

1.15–6.62

0.0225

Steps: >6000 vs 0

1.97

0.82–4.72

0.1299

Time since last infusion to activity start§:
>24 vs ≤24 h

2.65

1.05–6.62

0.0399

Last infusion dose, IU/kg

0.98

0.95–1.00

0.0607

Age

0.99

0.96–1.02

0.5006

1–120 min of activity vs no activity

2.68

1.06–6.75

0.0368

121–240 min of activity vs no activity

2.28

0.92–5.64

0.0760

>240 min of activity vs no activity
Time since last infusion to activity start§:

2.19
2.65

0.88–5.47
1.04–6.72

0.0921
0.0409

0.98
0.99

0.95–1.00
0.96–1.02

0.0595
0.4855

Every 30 min spent on lightly active activity

1.01

0.94–1.09

0.8197

Every 30 min spent on fairly active activity
Every 30 min spent on very active activity

1.02
0.92

0.80–1.22
0.68–1.25

0.8308
0.5969

Time since last infusion to activity start§:

2.61

1.02–6.69

0.0452

>24 vs ≤24 h
Last infusion dose, IU/kg

0.98

0.95–1.00

0.0594

Age

0.99

0.96–1.02

0.4492
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Model 1: Activity calories

Model 2: Steps performed

Model 3: Time spent on activities

>24 vs ≤24 h
Last infusion dose, IU/kg
Age
Model 4: Time spent on the activity by risk level

†

Notes: P-values of <0.05 indicate statistically significant associations. Logistic regression models were used to evaluate the dynamic association between activity and time
since last infusion on bleeding risk with time-varying activity level in the current cycle, time since last rAHF infusion to the beginning of the activity cycle, and age at baseline
(fixed covariate). Generalized estimating equations were used to account for intra-person correlations. ‡Among the 46 patients in the analysis, 19 had a total of 57 bleeds
reported as spontaneous. §Activity tracker data did not record the exact timing of activity, but reported the number of activity minutes by risk level daily. Therefore, the data
were structured by date for each individual.
Abbreviation: rAHF, antihemophilic factor (recombinant).

tracker data did not show that a longer time between last
rAHF infusion and start of physical activity (≤24 vs > 24
hours) was associated with significantly greater risk of occur
rence of bleeding reported by patients as physical activityrelated. Although most patients infused before physical
activity, nearly 65% of infusions occurred >24 hours
(35.3% ≤24 hours) before initiating physical activity. rAHF
infusion was timed more closely to physical activity and
occurred more frequently among patients engaging in higher-
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risk activities, although 60% of infusion intervals for level
2.5–3 activities exceeded 24 hours. Together, these findings
suggest that less than half of patients adjusted rAHF infusion
timing for higher-risk physical activities.
The study cohort presented in this analysis represented
a generally healthy population with hemophilia A, with
a number of pre-study bleeding episodes comparable with
that of prophylactically treated patients with severe hemophilia
A in the United States.15 Time since last infusion was not
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significantly associated with an increased risk of activityrelated bleeds, and this may be partially explained by patientreported categorization of bleeding types as “any”, “sponta
neous”, “activity-related”, or “other”. Some patients may have
had difficulty identifying an occurrence of bleeding as physical
activity-related vs spontaneous. Therefore, “activity-related”
occurrence of bleeding may have been under-reported.
The study design did not mandate for exact timing of
physical activities to be recorded; activity time was
reported in the eDiary as morning, afternoon, and night
(the statistical approach to these data was using 6-hour
cycles), and assumed all activities occurred before bleed
ing onset. While this methodology may accurately reflect
the sequence of physical activity and physical activityrelated occurrence of joint bleeding episodes, it may not
for other bleeding types (ie, spontaneous, any, and other).
The 6-hour cycles may therefore have been too imprecise
to robustly explore the relationship between timing of
rAHF infusion and physical activity and bleed risk.
Further, patient entries were retrospective and based on
memory, thus subject to recall bias.16 In addition, activity
tracker data may have been skewed towards including
physically active patients and those interested in tracking
physical activity. The results may therefore not be indica
tive of causal relationships and the findings should be
interpreted with caution. Further, it may suggest that the
National Hemophilia Foundation “Playing it safe” activity
listing could predict high-risk activities inaccurately.
Analysis by physical activity level as a group meant
that data were not skewed by individual patient physical
activity levels. Nevertheless, further research on patient
physical activity in relation to FVIII treatment patterns is
warranted, preferably with inclusion of pharmacokinetic
data so that correlations between FVIII levels and physical
activity can be investigated. The small sample size
of regression models for the physical activity level group
would likely reduce their ability to control for confounding
risk factors such as bleeding history.
Although joint health data were collected at baseline,
they were not included in the regression analysis
because of small sample size; therefore the study could
not assess whether patients with more joint disease at
baseline were at higher risk of injury-related and
reported spontaneous bleeding. Lastly, only one-third
of patients were ≥60% compliant with both eDiary and
activity tracker data entry.
ABRs for all bleeds in this study were similar to
bleeding rates from other real-world settings,17,18
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although somewhat higher than rates reported at year 3
of rAHF treatment in the observational AHEAD study,19
and after ≥5 years of rAHF treatment in the AHEAD
study.20 This may be explained by suboptimal prophy
laxis adherence compared with other studies.18
Hemophilia A treatment adherence rates vary across
studies due in part to lack of standardized estimation
methods21 and barriers to prophylaxis adherence in
a real-world setting.22 In the current study, adolescents
exhibited worse adherence than adults, which is consis
tent with findings from elsewhere.23 We observed
a small number of reported AEs or SAEs, none of
which were considered related to rAHF.

Conclusions
The findings of this study did not demonstrate that a longer
time between last rAHF infusion and physical activity start
was associated with risk of occurrence of bleeding
reported by patients as physical activity-related. Further
studies designed to address the limitations herein
described are needed to confirm the association between
physical activity level, timing of infusions, and the occur
rence of bleeding in patients with hemophilia A.

Data Accessibility
The datasets, including the redacted study protocol,
redacted statistical analysis plan, and individual participant
data supporting the results reported in this paper, will be
made available within 3 months from initial request to
researchers who provide a methodologically sound propo
sal. The data will be provided after its de-identification, in
compliance with applicable privacy laws, data protection,
and requirements for consent and anonymization. Data
requests should follow the process described in the Data
Sharing section on https://clinicaltrials.takeda.com/ and
https://vivli.org/ourmember/takeda/.
Additionally, Friedrich Maritsch (friedrich.maritsch@ta
keda.com) can be contacted regarding data-sharing
information.
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